(RTTNews) - PDS Biotech (PDSB), a late-stage immunotherapy company focused on cancer treatments, announced Thursday that the U.S. Food and Drug Administration or FDA has cleared its Investigational ...
Pilatus Biosciences Announces FDA Clearance of IND Application for PLT012, a First-in-Class Anti-CD36 Metabolic Checkpoint ...
SHENZHEN, China, May 28, 2025 /PRNewswire/ -- On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND ...
P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable ...
Quantum BioPharma Ltd. has announced an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application package for Lucid-21-302 ...
SAN FRANCISCO, CA / ACCESS Newswire / August 4, 2025 / CASI Pharmaceuticals, Inc. (CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ ...
In August 2024, Bin Xia Yang, a portfolio director at the pharmaceutical company Axcynsis Therapeutics, geared up to move the company’s new tumor-fighting antibody-drug conjugate into clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback